Alambic Investment Management L.P. reduced its holdings in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) by 58.7% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 62,556 shares of the specialty pharmaceutical company’s stock after selling 88,886 shares during the period. Alambic Investment Management L.P.’s holdings in AMAG Pharmaceuticals were worth $829,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Dupont Capital Management Corp lifted its holdings in AMAG Pharmaceuticals by 52.2% in the fourth quarter. Dupont Capital Management Corp now owns 30,031 shares of the specialty pharmaceutical company’s stock valued at $398,000 after buying an additional 10,300 shares during the period. Robeco Institutional Asset Management B.V. lifted its holdings in AMAG Pharmaceuticals by 19.5% in the fourth quarter. Robeco Institutional Asset Management B.V. now owns 778,488 shares of the specialty pharmaceutical company’s stock valued at $10,316,000 after buying an additional 126,780 shares during the period. Strs Ohio lifted its holdings in AMAG Pharmaceuticals by 26.6% in the fourth quarter. Strs Ohio now owns 51,000 shares of the specialty pharmaceutical company’s stock valued at $675,000 after buying an additional 10,700 shares during the period. Fox Run Management L.L.C. acquired a new position in AMAG Pharmaceuticals in the fourth quarter valued at approximately $449,000. Finally, Schwab Charles Investment Management Inc. lifted its holdings in AMAG Pharmaceuticals by 5.3% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 447,363 shares of the specialty pharmaceutical company’s stock valued at $5,928,000 after buying an additional 22,488 shares during the period.

Shares of AMAG Pharmaceuticals, Inc. (NASDAQ AMAG) opened at $12.90 on Thursday. The company has a quick ratio of 1.48, a current ratio of 1.59 and a debt-to-equity ratio of 0.94. The firm has a market cap of $455.22, a price-to-earnings ratio of -2.12 and a beta of 0.79. AMAG Pharmaceuticals, Inc. has a twelve month low of $11.93 and a twelve month high of $25.20.

AMAG has been the topic of several analyst reports. Zacks Investment Research lowered shares of AMAG Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, October 17th. B. Riley restated a “hold” rating and issued a $16.00 price objective on shares of AMAG Pharmaceuticals in a report on Tuesday, January 16th. Janney Montgomery Scott restated a “hold” rating on shares of AMAG Pharmaceuticals in a report on Tuesday, October 17th. Morgan Stanley cut their price objective on shares of AMAG Pharmaceuticals from $26.00 to $22.00 and set an “overweight” rating on the stock in a report on Friday, November 3rd. Finally, Piper Jaffray Companies restated a “hold” rating and issued a $15.00 price objective on shares of AMAG Pharmaceuticals in a report on Thursday, January 18th. Two analysts have rated the stock with a sell rating, ten have assigned a hold rating and two have issued a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $19.89.

ILLEGAL ACTIVITY WARNING: “Alambic Investment Management L.P. Has $829,000 Position in AMAG Pharmaceuticals, Inc. (AMAG)” was posted by Daily Political and is the sole property of of Daily Political. If you are accessing this story on another website, it was stolen and republished in violation of United States & international copyright & trademark legislation. The correct version of this story can be accessed at https://www.dailypolitical.com/2018/02/08/alambic-investment-management-l-p-has-829000-position-in-amag-pharmaceuticals-inc-amag.html.

AMAG Pharmaceuticals Company Profile

AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.

Want to see what other hedge funds are holding AMAG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG).

Institutional Ownership by Quarter for AMAG Pharmaceuticals (NASDAQ:AMAG)

Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.